ethyl 6-iodoimidazo[1,2-b]pyridazine-2-carboxylate | 1005786-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 6-iodoimidazo[1,2-b]pyridazine-2-carboxylate
• CAS: 1005786-10-6
• 化学式: C₉H₈IN₃O₂
• 分子量: 317.086
• InChiKey: IOFOQBGKWGVLDW-UHFFFAOYSA-N

物化性质

• 密度：
  1.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 6-iodoimidazo[1,2-b]pyridazine-2-carboxylate 在 盐酸 、 二苯基膦叠氮化物 、 水 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.34h， 生成 N-{3-[(2-aminoimidazo[1,2-b]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds

  摘要：

  To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1-6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = -7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity.

  DOI：

  10.1021/jm300126x
• 作为产物：
  描述：

  disodium hydrogenphosphate 、 3-溴丙酮酸乙酯 、 3-氨基-6-碘哒嗪 以 N,N-二甲基乙酰胺 为溶剂， 以44%的产率得到ethyl 6-iodoimidazo[1,2-b]pyridazine-2-carboxylate
  参考文献：
  名称：

  FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF

  摘要：

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。

  公开号：

  US20090137595A1

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Uchikawa Osamu

  公开号：US20100029619A1

  公开（公告）日：2010-02-04

  The present invention provides a compound represented by the formula (I): wherein ring A is a ring which is optionally further substituted; R 1 is a hydrogen atom or a substituent; R 2 is a hydrogen atom or a substituent; R 3 is a hydrogen atom or a substituent; R 4 is a hydrogen atom or a substituent; R 5 is a hydrogen atom or a substituent; R 6 is a hydrogen atom or a substituent; X is ═N— or ═C(Z)- (Z is a hydrogen atom or a substituent); when X is ═C(Z)-, Z and R 6 are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring, provided that when X is ═CH—, then R 6 is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same. The compound of the present invention has an ASK1 inhibitory action, and is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, inflammatory diseases and the like, and the like.

  本发明提供了一种化合物，其化学式表示为（I）：其中，环A是一个环，可以进一步取代；R1是氢原子或取代基；R2是氢原子或取代基；R3是氢原子或取代基；R4是氢原子或取代基；R5是氢原子或取代基；R6是氢原子或取代基；X是═N-或═C(Z)-（其中Z是氢原子或取代基）；当X是═C(Z)-时，Z和R6可以选择性地结合在一起，形成一个可选取代的环，与其相连的碳原子一起；但是当X是═CH-时，R6不是可选取代的2-哌啶基，不包括N-咪唑[1,2-a]吡啶-2-基-4-甲基苯甲酰胺、N-咪唑[1,2-a]吡啶-2-基苯甲酰胺和N-(7-甲基咪唑[1,2-a]吡啶-2-基)-苯甲酰胺，或其盐，并且含有该化合物的药物。本发明的化合物具有ASK1抑制作用，可用作药物，例如预防或治疗糖尿病、炎症性疾病等药物。
• Imidazo-pyridazinyl compounds and uses thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08273741B2

  公开（公告）日：2012-09-25

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大的激酶抑制活性的融合杂环衍生物及其用途。该化合物由式(I)表示，其中每个符号如规范中所定义，除了特定的化合物或其盐，以及含有该化合物或其前药的药物剂，该药物剂是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂、血管生成抑制剂、预防或治疗癌症的药剂、癌症生长抑制剂或癌症转移抑制剂。
• Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08034812B2

  公开（公告）日：2011-10-11

  The present invention provides an imidazopyridazine derivative compound having a potent kinase inhibitory activity and a pharmaceutical agent thereof useful for treatment or prevention of cancer and the like. One such compound is represented by the formula: or a salt thereof or a prodrug thereof. The pharmaceutical agent contains the imidazopyridazine derivative compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor, or a cancer metastasis suppressor.

  本发明提供了一种具有强效激酶抑制活性的咪唑吡啶并咪唑衍生物化合物及其药物制剂，用于治疗或预防癌症等疾病。其中一种化合物由以下公式表示：其中R1、R2、R3、R4、R5和R6的定义如文中所述。该药物制剂包含咪唑吡啶并咪唑衍生物化合物或其前药，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂、血管生成抑制剂、癌症预防或治疗剂、癌症生长抑制剂或癌症转移抑制剂。
• Fused heterocyclic derivative and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08044049B2

  公开（公告）日：2011-10-25

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大的激酶抑制活性的融合杂环衍生物及其用途。其中，化合物由式(I)表示：其中，除了特定的化合物或其盐外，每个符号如规范中定义，并且包含该化合物或其前药的药物剂量形式，该药物剂量形式是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂、血管生成抑制剂、预防或治疗癌症的药剂、癌症生长抑制剂或癌症转移抑制剂。
• US8044049B2
  申请人：——

  公开号：US8044049B2

  公开（公告）日：2011-10-25